1. Introduction {#sec1-ijerph-16-03839}
===============

Health care is a wide field whose effects focus not only on the health of the population; in general, we can talk about the contribution of effective health systems to the sustainable development of the countries or to environmental management. Public health is currently one of the most discussed social themes in many countries around the world. Socio-economic disparities in health outcomes appear to be a key issue for researchers and experts \[[@B1-ijerph-16-03839]\]. There have been several studies on health effectiveness that dealt with the socio-economic factors that affect health outcomes. The evidence showed the effects of childhood poverty on health and development \[[@B2-ijerph-16-03839]\]. Fernald et al. \[[@B3-ijerph-16-03839]\] also identified the link between child development and wealth and maternal education. Other important factors that affect health outcomes include accessibility to health care \[[@B4-ijerph-16-03839],[@B5-ijerph-16-03839],[@B6-ijerph-16-03839]\], education \[[@B7-ijerph-16-03839],[@B8-ijerph-16-03839],[@B9-ijerph-16-03839]\], the number of doctors \[[@B10-ijerph-16-03839]\] and the happiness and well-being of society \[[@B11-ijerph-16-03839],[@B12-ijerph-16-03839]\]. Last but not least, a significant negative impact of unemployment on self-assessed health and mental health was confirmed \[[@B13-ijerph-16-03839]\]. Poor health is widely recognized as a consequence of social disadvantage. Our study looks at the effectiveness of health care in terms of the relationship between health expenditure and health outcomes in various health care financing systems in OECD countries. The main idea of the present research arose from the assumption that increased funding must be positively reflected in a particular variable that determines the effectiveness of health care and that if systems are well designed, they should produce comparable outputs.

Literature Review
-----------------

The aim of policy-makers is to provide a level of health care comparable to that provided in Western European countries. Strengthening the health system through the implementation of health standards can be one method to significantly improve in performance and quality of health care services \[[@B14-ijerph-16-03839]\]. However, not only financial resources must be allocated to a sustainable long-term health care system. Cost effectiveness is extremely important to achieve the objectives of fiscal sustainability and access to quality health care for all citizens in a given country \[[@B15-ijerph-16-03839]\]. The policy makers of many countries have observed a fluctuation in health care spending, with the country's health care system considerably affecting national health care spending \[[@B16-ijerph-16-03839]\]. The European Commission \[[@B17-ijerph-16-03839]\] presented the Joint Report on Health Care and Long-Term Care Systems and Fiscal Sustainability, highlighting selected key challenges for health and long-term care in the European Union (EU), as well as improving the fiscal sustainability of public health spending. According to this report, spending on health and long-term care has increased and displays a growing tendency in all EU member states. In 1990 health spending presented about 5.8% of gross domestic product (GDP), 8.7% percent in 2015 and is projected to rise to 12.6% of GDP by 2060 \[[@B18-ijerph-16-03839],[@B19-ijerph-16-03839]\]. This figure is closely related to life expectancy, which, due to demographic changes and advanced technologies, will increase to 89.1 years for women and 84 years for men by 2060, resulting in a significant increase in the proportion of seniors in the total population \[[@B17-ijerph-16-03839]\]. In the relationship between expenditure and outcomes for health care, previous studies \[[@B20-ijerph-16-03839],[@B21-ijerph-16-03839],[@B22-ijerph-16-03839]\] reported different effects, so the causal relationship between these two variables is not entirely clear.

As health capital plays a significant role in a country's economic growth from a long-term perspective, the health care system in a country should be supported and the World Health Organization's recommendations on state health care spending should be considered. Investing in health care is important in terms of formation of the health capital. Health capital crucially functions in a country's economic growth and can be identified by many indicators \[[@B23-ijerph-16-03839],[@B24-ijerph-16-03839]\]. Many researchers examined the relationship of health expenditure and GDP, a bi-directional causal link between these variables was indicated. To this end, policies seek to improve the well-being of the population in the long-term by increasing health expenditure \[[@B25-ijerph-16-03839]\]. Sharma \[[@B26-ijerph-16-03839]\] investigated the relationship between health and economic growth. The results showed that the health status of the population, which is proxied by life expectancy, has a positive and significant effect on real per capita income as well as economic growth. The results reported by Boachie \[[@B27-ijerph-16-03839]\] showed that good health significantly promotes economic growth, both in the short- and long-term.

Development policy should therefore aim to increase health sector investment to improve the health conditions of the population. We can ask the question, what effective alternatives can be implemented to increase health expenditures in countries with a diverse population structure. In more developed countries, a strong positive relationship exists between national income and total health expenditure \[[@B28-ijerph-16-03839]\], but, conversely \[[@B29-ijerph-16-03839]\], in low-income countries, health care spending is less sensitive to national income changes. The increase in the national income in the country does not necessarily correspond to sufficient improvement in financing of health care. Another influential determinant of the amount of health expenditure is the demographic aging of the population \[[@B30-ijerph-16-03839]\]. Howdon and Rice \[[@B30-ijerph-16-03839]\] found that population morbidity, together with the current increase in life expectancy, exert competitive and counterbalancing pressures on health spending. Similar results have been reported by other authors \[[@B31-ijerph-16-03839],[@B32-ijerph-16-03839]\] who examined the relationship between the input and output dynamics of health care systems, and showed that long-term viability has steadily increased and child mortality rates have fallen, together with rising health care spending. Van den Heuvel and Olaroiu \[[@B20-ijerph-16-03839]\] confirmed their finding that the relationship between health expenditure and health care outcomes is complex and unclear, as spending on health care affects health outcomes. For this reason, the authors stated that without careful determination of the causes influencing this relationship, the effects of increasing or reducing health care costs may lead to over- or under-estimation. Improving health care management helps to positively increase the efficiency of health spending \[[@B33-ijerph-16-03839]\].

Average life expectancy at birth is a commonly used measure of health system efficiency, economic development, and a key indicator of people's well-being. For the management of public health resources, Cervantes et al. \[[@B34-ijerph-16-03839]\] highlighted life expectancy at birth as an indicator able to measure the performance of the health system. Health care spending for countries has heterogeneous effects on life expectancy, due to differences in population characteristics and economic factors \[[@B22-ijerph-16-03839]\]. Many studies \[[@B22-ijerph-16-03839],[@B35-ijerph-16-03839],[@B36-ijerph-16-03839]\] evaluated the variation in the impact of health expenditures by using linear regression, and the results showed that increasing health care spending in low life-expectancy countries can produce significant returns on the life expectancy of the population while reducing global inequalities in long-term care. Previous results \[[@B22-ijerph-16-03839]\], analyzed by quantile regression, showed rising health expenditure positively affects especially low-life countries. Bein et al. \[[@B37-ijerph-16-03839]\] also confirmed a strong and positive relationship between total health care spending and life expectancy. Contrasting results \[[@B38-ijerph-16-03839]\] have been observed among the U.S. population, where health care spending increases and life expectancy are lower than in most industrialized countries. Studies have confirmed the significant relationship between social expenditure and life expectancy. Reynolds and Avendano \[[@B38-ijerph-16-03839]\] stated that increasing social expenditure positively affects life expectancy and this positive relationship is stronger than the relationship between health expenditure and life expectancy. By testing, they found that maximum spending on education and incapacity can increase life expectancy to 80.12 years. Other U.S. research \[[@B39-ijerph-16-03839]\] examined differences between health expenditure and social expenditure and assessed their association with health indicators. The authors \[[@B39-ijerph-16-03839]\] stated that there is a significant relationship between health expenditure and low birth weight and maternal mortality, social expenditure was significantly associated with life expectancy, infant mortality, and increased potential life years lost.

Perceived health status is the most frequently applied measure of health in empirical research \[[@B40-ijerph-16-03839],[@B41-ijerph-16-03839]\]. Several authors investigated the relationship between health expenditure and self-assessed health status \[[@B42-ijerph-16-03839]\], and the limited effect of expenditure was confirmed \[[@B43-ijerph-16-03839]\]. Another measure of health care effectiveness is mortality. Heijink et al. \[[@B44-ijerph-16-03839]\] stated that countries with an above-average expenditure growth showed above-average reductions in avoidable mortality. The findings of other study showed that, between 2011 and 2014, health expenditure in Italy decreased, compared to previous years, and the overall mortality increased \[[@B45-ijerph-16-03839]\]. The results of other studies \[[@B46-ijerph-16-03839],[@B47-ijerph-16-03839]\] also suggested that reduced health expenditure is related to increased population mortality. Among the health outcomes that are affected by health and social expenditure, Bradley et al. \[[@B48-ijerph-16-03839]\] also identified mortality rates for lung cancer and acute myocardial infarction. On the other hand, based on data on acute myocardial infarction, Moscone et al. \[[@B49-ijerph-16-03839]\] found that health expenditure had a little impact on health outcomes, but the authors highlighted the importance of how the health expenditure is spent. Cost-effective health care could improve the outcomes of patients with acute myocardial infarction \[[@B50-ijerph-16-03839]\], which means improving health outcomes. The coexistence of diabetes in people with acute myocardial infarction is common. Zhou et al. \[[@B51-ijerph-16-03839]\] confirmed that excess expenditure associated with diabetes was substantial for people with acute myocardial infarction (AMI) or who had had an acute ischemic stroke (AIS), and they highlighted the need for both the prevention and better management of diabetes among AMI and AIS patients, which in turn may lower the financial burden of treating these conditions. At the global level, there has been an evident increase in the cost of diabetes \[[@B52-ijerph-16-03839]\], which imposes a large economic burden on health care systems across the world \[[@B53-ijerph-16-03839],[@B54-ijerph-16-03839]\]. Jonsson \[[@B55-ijerph-16-03839]\] determined the relations of diabetes with economic output, indicating that diabetes accounts for 2--3% of the total health care budget in every country. Therefore, an increase in diabetes incidence and prevalence translates into a significant economic impact. The evidence revealed that the growth of expenditure relates to the growing prevalence of diabetes, and the excess cost associated with the incidence of treated type 2 diabetes increases by an average of 4% per year in France. This excess cost is mainly due to primary care expenditure, which is essentially related to drugs, nursing care, and medical devices and services \[[@B56-ijerph-16-03839]\]. Schofield et al. \[[@B57-ijerph-16-03839]\] also demonstrated that the indirect costs of diabetes through lost productive life years are considerable, both at the individual and national level. Studies on the direction of the relationship between health expenditure and health care quality are inconsistent. Most studies revealed that the association between expenditure and quality is small to moderate, regardless of whether the direction is positive or negative \[[@B58-ijerph-16-03839]\].

According to Ibrahim and Daneshvar \[[@B59-ijerph-16-03839]\], reduction in health expenditure does not necessarily reduce efficiency of health care system if the operational and technical aspects are improved. Another study \[[@B60-ijerph-16-03839]\] reported that information and communication technologies can improve the level of health care services. Stefko et al. \[[@B61-ijerph-16-03839]\] identified and quantified the impact of medical technologies (magnetic resonance devices, computed tomography devices) on the efficiency of the health care facilities. The authors of other study \[[@B62-ijerph-16-03839]\] detected differences in the performance of the health care systems. These differences reflect various co-innovations and technologies given the technology available.

The relationship between expenditure on health and life expectancy and the health status of the population points to the existence of significant differences between countries and suggests that health policies should focus on reducing health inequalities among countries in the EU. A deeper understanding of the determinants of public spending on health care may lead to more effective design of efficient health policies \[[@B31-ijerph-16-03839],[@B63-ijerph-16-03839]\].

2. Materials and Methods {#sec2-ijerph-16-03839}
========================

2.1. Aim of Research {#sec2dot1-ijerph-16-03839}
--------------------

The primary objective of the research in the present study was to determine the effectiveness of health care in classifying health care financing systems from a sample of OECD countries over the period 2012--2017. The main focus of this study was to determine the relationships between health expenditure, considered as the percentage of a country's GDP (Expend_H), and selected determinants of health effectiveness: average life expectancy at birth (Life_expect), perceived health status (Self_rep_H), the health care index (HC_index), deaths due to acute myocardial infarction (AMId) per 100,000 persons, and deaths due to diabetes mellitus (DIAd) per 100,000 persons from a sample of OECD countries with respect to the type of health care financing system. In addition to the aforementioned primary focus, the relationships between individual systems (Multiple Insurance Funds or Companies---MI, the National Health Care System---NHS, and the Single-Payer Model---SPM) and selected variables that determine the effectiveness and financing of health care were also assessed.

Based on the above, a research question was formulated:

RQ: Do health care financing systems show differences in terms of the effectiveness of health care provision?

Based on the research presented in the previous chapter, this research effort will aim to verify the following hypotheses:

H1: It is assumed that in selected financing systems, health expenditure has a significant impact on life expectancy at birth.

H2: It is assumed that in selected financing systems, health expenditure has a significant impact on perceived health status.

H3: It is assumed that in selected financing systems, health expenditure has a significant impact on the health care index.

H4: It is assumed that in selected financing systems, health expenditure has a significant impact on deaths from acute myocardial infarction.

H5: It is assumed that in selected financing systems, health expenditure has a significant impact on deaths from diabetes mellitus.

2.2. Description of the Sample {#sec2dot2-ijerph-16-03839}
------------------------------

The sample included all countries of the OECD, including Latvia, which was officially accepted as a member on 5 July 2018 \[[@B64-ijerph-16-03839]\], and Australia, Austria, Belgium, Canada, Chile, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, the Netherlands, New Zealand, Norway, Poland, Portugal, Slovak Republic, Slovenia, Spain, Switzerland, Turkey, United Kingdom, and the United States. As Sweden has a different system of financing (local health systems that serve distinct geographic regions), we excluded it from the analysis.

The first variable entered into the analysis was total health expenditure (Expend_H) expressed as a percentage of GDP from the OECD \[[@B65-ijerph-16-03839]\] database for the period 2012--2017. Expend_H measures the final consumption of health care goods and services (i.e., current health expenditure), including personal health care (curative care, rehabilitative care, long-term care, ancillary services, and medical goods) and collective services (prevention and public health services as well as health administration), but excluding spending on investments. Health care is financed through a mix of financing arrangements including government spending and compulsory health insurance (Government/compulsory) as well as voluntary health insurance and private funds such as households' out-of-pocket payments, non-government organizations (NGOs) and private corporations (Voluntary). This indicator is presented as a total and by type of financing (Government/compulsory, Voluntary, or Out-of-pocket) and is measured as a share of GDP, as a share of total health spending and in USD per capita (using economy-wide public private partnerships) \[[@B65-ijerph-16-03839]\].

The second variable entering the analysis, Life_expect, is an average life expectancy at birth from the OECD \[[@B66-ijerph-16-03839]\] databases for the period 2012--2017. Life_expect is defined as how long, on average, a newborn can expect to live if current death rates do not change. However, the actual age-specific death rate of any particular birth cohort cannot be known in advance. If rates are falling, actual life spans will be higher than life expectancy calculated using current death rates. Life_expect is one of the most frequently used health status indicators. Gains in Life_expect can be attributed to a number of factors, including rising living standards, improved lifestyle, better education, and greater access to quality health services. This indicator is presented as a total, by sex, and is measured in years \[[@B66-ijerph-16-03839]\].

The third variable, Self_rep_H, represents the percentage of the population that provided a positive response (good or very good) on the five-part scale (very good, good, fair, bad, or very bad) to the question "How is your health in general?". This variable was obtained from OECD \[[@B67-ijerph-16-03839]\] databases for the period 2012--2017.

The fourth variable in the research is the variable defining health care, HC_index. This was obtained from the NUMBEO \[[@B68-ijerph-16-03839]\] database (2012--2017) and is an aggregated index of an online survey. Seven satisfaction-oriented variables are included in the index (skill and competency of medical staff, speed in completing examination and reports, equipment for modern diagnosis and treatment, accuracy and completeness in filling out reports, friendliness and courtesy of the staff, responsiveness (waiting time) in medical institutions, and convenience of location for you). The output ranges from 0 to 100.

The fifth variable, AMId, represents deaths from acute myocardial infarction per 100,000 people. This variable was obtained from OECD \[[@B67-ijerph-16-03839]\] databases for the period 2012--2017. Myocardial infarction is defined by the demonstration of myocardial cell necrosis due to significant and sustained ischaemia. It is usually, but not always, an acute manifestation of atherosclerosis-related coronary heart disease \[[@B69-ijerph-16-03839]\].

The sixth variable that is considered in the analysis, DIAd, represents deaths from diabetes mellitus per 100,000 people. This variable was obtained from OECD \[[@B67-ijerph-16-03839]\] databases for the period 2012--2017. Diabetes mellitus describes a metabolic disorder of multiple aetiology, characterized by chronic hyperglycaemia, with carbohydrate, fat and protein metabolism disturbances, resulting from defects in insulin secretion, insulin action, or both. The effects of diabetes mellitus include the long-term damage, dysfunction and failure of various organs \[[@B70-ijerph-16-03839]\].

One more variable, and hence the determinant of financing of the health care system, HC_System, was included in the analyses. Among the selected OECD countries, three systems of financing are recognized: (1) A national health care system covering the country as a whole (NHS), (2) a single health insurance fund (single-payer model; SPM) and (3) multiple insurance funds or companies (MI) \[[@B71-ijerph-16-03839]\]. Stated information was gathered from the Health Systems Characteristics Survey conducted by the OECD in 2012 and 2016. Latvia was not yet a member of the OECD, so the information was obtained from the Latvian health care website \[[@B72-ijerph-16-03839]\].

[Table 1](#ijerph-16-03839-t001){ref-type="table"} provides the input data (based on mean) for variables such as country, health care financing system (HC_System), total health expenditure as a percentage of GDP (Expend_H), average life expectancy at birth (Life_expect), perceived health status (Self_rep_H), health care index (HC_index), deaths from acute myocardial infarction per 100,000 people (AMId), and deaths from diabetes mellitus per 100,000 people (DIAd) for the period 2012--2017.

2.3. Analytical Process Description {#sec2dot3-ijerph-16-03839}
-----------------------------------

In the first step of the analysis, a descriptive analysis was used to process collected health outputs to provide information about the achieved values of the countries as a whole, but also in classifying HC_System. The descriptive analysis provided the number of countries (*N*), the arithmetic mean (*M*), and the standard deviation (*σ*) of health care outputs. This was followed by an analysis of the association between health care financing systems and selected indicators of health care effectiveness (effect size). The coefficient, *η^2^*, was used for this analysis. The output of this analysis provides information regarding whether there is a relationship between HC_System and a certain effectiveness indicator. This was followed by a logistic binomial regression analysis, the results of which show that a change in the value of a particular health variable indicates a change in the probability of acquiring a particular HC_System. The application of this analysis was determined by the MCE (misclassification error), the Null and Residual Deviance and the Hosmer and Lemeshow GOF test. The dataset was divided, according to a dummy variable of the health system, into training (80%) and testing (20%) datasets, where the confusion matrix and then the misclassification error were calculated. A lower value represents a more positive result, and the greatest emphasis should be placed on the difference between the MCE training and testing data. Additionally, the difference between the null and residual deviance should be determined, so that the result will be more positive for the model itself (the more relevant model), when the difference is smaller. The Hoslem test is suitable for analyzing the *p*-value. If the *p*-value exceeds the rate of 0.05, the model is considered to fit well. The following part of these analyses was devoted to expressing the impact of Expend_H on the selected variables of health care effectiveness. Regression analysis (Simple linear regression, Least Trimmed Squares Robust (High Breakdown) Regression, and HC3 (Heteroskedasticity-Consistent standard error estimator) robust base regression) was used for this purpose. The selection of a particular model, as well as the evaluation of the model conditions, was carried out with the help of an F test for the individual effects (refuting the effect of time in years), a stationary---Augmented Dickey-Fuller Test, an outlier---Bonferroni Outlier Test; a heteroscedasticity---Breusch-Pagan Test and the determination coefficient *R^2^*. Correlation analysis (Spearman *ρ*) was also included in this part of the analyses, completing the information of linking the various variables of health care effectiveness in the classification of health care financing systems, as well as the overall information. The last part of the analyses considered the outputs of the correspondence analysis, aiming to assess the tightness of the interconnection between health care financing systems and the selected health care effectiveness variables, which were converted into quartiles. The analysis was carried out using the Eurlidian distance, and its objectivity was assessed on the basis of the *χ^2^* coefficient and correlation (Pearson *π*). Analysis data were processed in MS Excel (Microsoft, Redmond, WA, USA) and using the RStudio (RStudio, Inc., Boston, MA, U.S.) application.

3. Results {#sec3-ijerph-16-03839}
==========

This section discusses the analytical processes determining the accuracy of our established research questions. As described in the methodology, the first part of the analyses shows descriptive statistics on the variables of health care effectiveness and the variable of the total health care financing, but also on the classification of individual systems of health care financing. The following section is devoted to determining the relation between the selected health care effectiveness variables and the variable representing Expend_H within individual HC_System. The analytical processing of the issue involves expressing the impact of Expend_H on the selected health care effectiveness variables, as well as a secondary determination of the relation of the selected variables to each other. These procedures are carried out through the classification of health care financing systems in order to understand the differences between these systems. These analyses are followed by a final section that presents the correspondence analysis.

3.1. Descriptive Analysis {#sec3dot1-ijerph-16-03839}
-------------------------

This section consists of a descriptive analysis, an assessment of the effect size of the health care financing system's on given health outputs, analysis of relationships, and correspondence analysis visualizations. [Table 2](#ijerph-16-03839-t002){ref-type="table"} provides the results of the calculation of the descriptive statistics.

[Table 2](#ijerph-16-03839-t002){ref-type="table"} shows the mean (*M*), the standard deviation (*σ*), and the frequency (*N*) of the selected indicators Expend_H, Life_expect, Self_rep_H, HC_index, AMId and DIAd providing an overview of the (total) outputs achieved by all OECD countries as well as the second-degree ranking in the individual HC_System, i.e., NHS, SPM, and MI. The highest average Expend_H was found under the MI financing system. MI had an average Expend_H of 9.72% of GDP, which is 1% more than the average Expend_H in all OECD countries. For Life_expect, we noted that in countries applying the NHS model, Life_expect was the longest, averaging 80.80 years. The shortest Life_expect was in countries with SPM, averaging 79.65 years. For Self_rep_H, countries applying NHS had the highest proportion of the population assessing their health positively, i.e., either good and very good. Examining the HC_index values, [Table 2](#ijerph-16-03839-t002){ref-type="table"} shows that the countries applying the MI model had the highest average value. The highest mortality rates for AMId and DIAd are recorded by countries applying the MI system. Based on these variables, countries applying the SPM model achieve sub-average values not only compared with other models but also in comparison with the average outputs of the OECD countries as a whole. Possible limitations may be the specificity of the countries themselves, their characteristics, performance, level of human development, macro-environment and micro-environment, aspects the social system, and education---the effects of other dimensions particular to specific countries.

3.2. Relation between Health Care Financing Systems and Selected Health Indicators {#sec3dot2-ijerph-16-03839}
----------------------------------------------------------------------------------

[Table 3](#ijerph-16-03839-t003){ref-type="table"} shows the effect size of the nominal (qualitative) variable HC_System on selected health care indicators. The table shows how HC_System affects Expend_H, Life_expect, Self_rep_H, HC_index, AMId and DIAd. In the Life_expect, Self_rep_H, HC_index and DIAd indicators, we identified a small but not negligible effect rate. In the case of Expend_H, this was a moderate effect. AMId it was negligible rate \[[@B73-ijerph-16-03839]\].

[Table 3](#ijerph-16-03839-t003){ref-type="table"} shows information on the possibility of a certain relation between health variables and health care financing systems. In the next step, the impact of these health variables on the likelihood of the appearance of a given HC_System is assessed.

From the results presented in [Table 4](#ijerph-16-03839-t004){ref-type="table"}, it was decided that the Hosmer and Lemeshow goodness of fit test, which includes the H~0~: a model is fit well, will be conducted first. Since the value of *p* in models 1 and 2 is lower, it is reasonable to lean towards the alternative of the statistical hypothesis, mentioned above. For this study, this means that the model has some flaws. The Deviance principle states that differences between Null and Residual values should be as small as possible, but Model 1 and 2 show higher values. The misclassification error (MCE) should be as small as possible, and although the measured values are higher, they are still acceptable. The regression model was based on a modern methodology of comparing training (80%) and testing (20%) data. The MCE should be as small as possible. The above values can be assessed, and the most positive result was found for model 3. The collinearity (VIF) of these models was also assessed, where for Model 1, the highest measured rate was that of Expend_H, which was approximately 2.72; for Model 2, the highest measured rate was that of Life_expect, which was 2.11; and for Model 3, the highest measured VIF was that of Life_expect, which was approximately 2.06. Based on this information, it was found that the degree of collinearity in the models was acceptable.

As mentioned, the models in question are not ideal, but they are sufficient to describe the effects of the selected variables. [Table 5](#ijerph-16-03839-t005){ref-type="table"} shows the output of the models. Based on the results in [Table 5](#ijerph-16-03839-t005){ref-type="table"}, it was decided to first assess the significance of the impact. If the impact is significant, it is appropriate to assess the coefficients. The coefficients are evaluated firstly through their polarity and secondly through their absolute value. If the polarity is positive, e.g., with the MI system for Expend_H, it is possible to say that with increasing Expend_H, there is a significant increase in the likelihood that the system will be an MI and not another system (NHS, SPM). As can be correctly concluded, certain health variables tend to be inclined toward specific funding systems. It can therefore be assumed that, in certain funding systems, there will be different effectiveness in terms of Expend_H. The following sections of the study address this assumption.

3.3. Impact of Health Expenditure on Selected Health Care Indicators {#sec3dot3-ijerph-16-03839}
--------------------------------------------------------------------

[Table 6](#ijerph-16-03839-t006){ref-type="table"} shows the outcomes of the whole process of selecting the most appropriate mechanism for determining the impact of Expend_H on the selected health care indicators. Since the time series (2012--2017) was entered into the data, a test was applied to determine the suitability of the panel model of regression analysis (fixed effect), if the *p-*value is greater than 0.05, and the classical OLS model (H~0~: the panel variable has a significant effect) seems to be more suitable. As can be seen, the reported *p-*value is, in all cases, almost equal to one. While there was only a small time series, the stationarity was tested (H~0~: the series has a unit root (i.e., non-stationary)). As is evident, there is a stationary series in all cases, so time does not need to be taken into account. The outlier defines the *p-*value of the significance of the first most significant outlier (H~0~: the outlier is not significant). The decision concerning presence was also supported by the analysis of the model visualizations, which are not mentioned here. Based on the Gauss-Marks theorem, the heteroscedasticity (H~0~: the constant residual variance) for BLUE (the Best Linear Unbiasted Estimate) is an extremely important element. In models in which significant heteroscedasticity occurred, the coefficients were derived using the HC3 estimator. The Reg. Model column points to the most suitable model, OLS is the simple linear regression Ordination Least-Squares; OLS HC3 is the OLS with the HC3 estimator; and LTS is the Least Trimmed Squares Robust (High Breakdown) Regression. The *R^2^* coefficient of determination, which is shown in the last column, represents a measure of what portion of the percentage of the variability of the dependent variable is explained by the independent variable, and a suitable rate is greater than approximately 30% (0.3). [Table 7](#ijerph-16-03839-t007){ref-type="table"} determines the statistical significance of the models and the rate of the coefficients affecting the dependent variable. This output can be seen as one of the most valuable in terms of assessing the ideas of this study.

First of all, it is advisable to focus on the probability of the models (Sig.), and the zero statistical hypothesis (H~0~: the impact is not significant) is rejected for most models. In view of the assumptions presented in the section describing the methodology, it is appropriate to point out that each of the formed hypotheses (H1--H5) has been confirmed, so the effect of Expend_H on health care effectiveness outputs is evident for the selected health care systems. Values of *p* less than 0.05 are highlighted. A very important indicator of the level of impact is the coefficient, *β~1~*, which plays an irreplaceable function in comparing the impact of different HC_System. The highest value of the coefficient, *β~1~*, between health care systems is highlighted. In interpreting and determining the impact differences, i.e., the effectiveness of health care, the coefficient of determination must also be taken into account. In the Life_expect models, the NHS system (*R^2^* = 0.5716) appears to be the most effective, and the other two systems show lower coefficients and *R^2^* values, which could easily be challenged. The recommendation is to perceive other outputs in this way as well. At this moment, it is clear, from the above, that not every funding system declares the same outputs in relation to the impact of funding on health outcomes. The NHS funding model even appears to be ineffective in Model 10. These outputs indicate some system weaknesses.

[Table 8](#ijerph-16-03839-t008){ref-type="table"} shows the forecast outputs for the value of 8.72, which represents the total average rate of Expend_H (%), as a percentage of a country's GDP. More positive predictive outputs of systems are highlighted. Attention should be paid to the fact that the diseases that are frequent in developed countries (AMId, DIAd) were not, as expected, significant impacted by expenditure. It is also possible to deduce, from the above, the shortcomings of the systems, which are identifiable in variables where relations have not been confirmed, meaning that the models showed a relatively low *R^2^* value. For example, if the NHS model is taken into consideration, the relation between Expend_H and AMId or DIAd did not have to be confirmed, as the population ages, and thus the incidence of these diseases becomes more frequent. If these connections were to be considered in an exact way, it is necessary to know the extent to which the individual variables are related to each other, and this information is provided in [Table 9](#ijerph-16-03839-t009){ref-type="table"}.

[Table 9](#ijerph-16-03839-t009){ref-type="table"} is divided into four sections: the first three determine the link between the individual systems of health care financing, and the last section shows the overall correlation. Above the diagonal, the measure of the relationship (Spearman *ρ*) is shown, and below the diagonal, the value of *p* is shown. Secondly, health care systems can be read and compared in a simplified way in terms of expenditure effectiveness (Expend_H).

3.4. Correspondence Analysis {#sec3dot4-ijerph-16-03839}
----------------------------

In the correspondence analysis application, we grouped the OECD countries into four quartiles: Q1, Q2, Q3, and Q4. The lower quartile Q1 (\<Q1) represents 25% of OECD countries with the lowest results for the surveyed variable. Conversely, the top quartile Q4 (\>Q3) contains 25% of OECD countries with the highest values for the surveyed variable. [Table 10](#ijerph-16-03839-t010){ref-type="table"} shows that countries such as Australia (NHS), Israel (MI), and Norway (NHS) are countries with the most promising results of Life_expect, Self_rep_H and HC_index. Other countries with favorable values include Austria (MI), Luxembourg (SPM), New Zaeland (NHS) and Spain (NHS). The countries that achieve the least attractive values of the examined variables are Hungary (SPM), Latvia (NHS), Poland (SPM) and Turkey (SPM).

[Table 11](#ijerph-16-03839-t011){ref-type="table"} quantifies the basic outputs of the correspondence analysis for the selected variables in relation to the HC_System. The greatest importance can be attributed to the sig. line, which displays information in the statistical significance of linking specific variables. As is clear in the case of AMId, this is not a significant relation. The last line provides an idea of the relations between the analyzed variables. The minimum acceptable value may be considered to be 0.2. The eigenvalue determines the degree of the importance of dimensions.

The most significant outputs of this section are the links between the categories (quartiles) of the selected health variables and the individual HC_System (MI, NHS, SPM), as shown in [Figure 1](#ijerph-16-03839-f001){ref-type="fig"}. The basic rule is that the closer the categories are to each other, and at the same time the further away from other categories of the analyzed variables, the more significant the output. When interpreting [Figure 1](#ijerph-16-03839-f001){ref-type="fig"}, it is necessary to take into account the scale of axes X (Dim1) and Y (Dim2), as not all graphs have the same scales.

Focusing on linking the funding system to health expenditure (Expend_H\_Q), the closest link that can be identified is that between MI and Q3, which can be interpreted as the highest expenditure in this system, so one could expect that the effectiveness of the health care in system MI will be the highest. In terms of funding, the NHS has the second highest expenditure, and the sample with the lowest funding rate centers around the SPM system. This relation has the highest correlation rate (0.75). The next graph shows the link between the funding system and life expectancy at birth (Life_Expect_Q), where the sample with the lowest Life_Expect appears to be from the SPM system, which can be characterized as a system with a lower Expend_H. The highest Life_Expect at birth is associated with the NHS system. The correlation rate for this relation is equal to approximately 0.31. As for the perceived health status (Self_rep_H\_Q), the most positive outputs can be attributed to the SPM system, and the least positive outputs can be attributed to the NHS system. The correlation rate for this is approximately 0.47. Very similar outputs are also shown in the graph assessing the health care index (HC_index_Q), where the SPM system has the least positive outputs, and the MI and NHS systems appear to be more effective. The correlation rate is 0.4. The relations in the previous graph should be interpreted with some caution, considering the outputs shown in [Table 11](#ijerph-16-03839-t011){ref-type="table"}.

4. Discussion {#sec4-ijerph-16-03839}
=============

The fact that health capital plays a significant role in a country's economic growth from a long-term perspective was confirmed in several studies \[[@B74-ijerph-16-03839],[@B75-ijerph-16-03839]\]. Health of the population is an important determinant of economic development because a healthy population means higher productivity \[[@B27-ijerph-16-03839],[@B76-ijerph-16-03839]\]. A healthy (laborable) population is the driving force of every economy. To increase economic performance, long-term economic development, or improve the quality of life in a country, adequate health care must be provided that reflects the opportunities for active product creation in the economy. For the improvement of national health and quality of life, some countries should actively look to optimize policy related to health expenditure, such as by enhancing the efficiency of health costs to promote sustainable economic development \[[@B77-ijerph-16-03839]\]. Investing in health care is an investment in human resources, which currently represent an indispensable part of product creation in every economy. For this reason, the relationship between the amount of health expenditure and outputs reflecting the effectiveness of health care in countries must be understood.

The results show the relationships between health expenditure and health care effectiveness represented by selected health care outputs (Life_expect, Self_rep_H, HC_index, AMId and DIAd) from a sample of OECD countries. Many authors \[[@B37-ijerph-16-03839],[@B44-ijerph-16-03839]\] confirmed the positive relationship between health expenditure and health outcomes, but we offer a new perspective on the issue. We emphasize that when identifying this relationship, the system of financing the health care in the country must be considered as each system responds differently to the change in the amount of health expenditure, and no each system has to respond to a change in the amount of health expenditure.

By focusing on the links between health expenditure and life expectancy at birth in relation to the outcomes of both regression and correlation analysis, it is possible to speak of the existence of a certain relation (in the contextual analysis, the relationship did not appear only in the NHS system). These results partially confirm the results of the study of Bein et al. \[[@B37-ijerph-16-03839]\], who indicate the existence of a positive relationship. A very similar output can be seen in the relationship between health expenditure and perceived health status, where there is no significant relationship in SPM. On the other hand, Pierard \[[@B43-ijerph-16-03839]\] talks about the limited effect of expenditure. The results also reveal a partially unprovable relationship between health expenditure and the health care index. The regression analysis outputs showed the relationship in two of the three systems examined, but with a low coefficient of determination. The correlation analysis outputs complement this finding and show a significant output only for the NHS system. The other two cases show a questionable link, confirming an inconsistent connection \[[@B58-ijerph-16-03839]\]. The negative relationship between health expenditure and deaths from acute myocardial infarction can be stated in the case of the MI system, which indicates that a higher expenditure can predict a decrease in acute myocardial infarction death. These findings partially correlate with the claims made by Bradley et al. \[[@B48-ijerph-16-03839]\] and Moscone et al. \[[@B49-ijerph-16-03839]\]. The relationship between health expenditure and deaths from diabetes mellitus was also analyzed, and the expected negative relationship occurred only in the MI and SPM systems. Based on this and the findings of the study of Baudot et al. \[[@B56-ijerph-16-03839]\], it is possible to assume that an increased incidence of diabetes increases health expenditure, and an increase in health expenditure can result from a reduction in the number of deaths from diabetes mellitus.

In the first part of our analyses, the relationship between the health care financing system and selected variables that determine the effectiveness of health care was examined. A relationship has been identified, where the highest rate of association manifests itself in health expenditure, and the lowest manifests itself in deaths from acute myocardial infarction per 100,000 persons. Subsequently, a logistic regression analysis was applied in order to point out the increasing probability of the existence of a certain system under the influence of the selected variables of health care effectiveness in OECD countries. The probability that a given subject will have an MI system applied, compared to other systems, is significantly increased as health expenditure increases and the rate of diabetes mellitus deaths per 100,000 persons increases. However, the probability decreases as life expectancy at birth increases. These outputs tell us that the MI system is applied in countries where the life expectancy at birth is lower than in other countries, but where there is a higher expenditure on health care and more diabetes mellitus deaths, so there is some mismatch between health care funding and increasing health levels. The basic premise of economic theory is that if an input increases, the output should also increase. The NHS model is more likely to occur in countries with higher rates of a good or very good perceived health status and lower deaths from diabetes mellitus (Self_rep_H has a significant impact at 0.03, and DIAd is even more significant, i.e., the *p*-value is approximately 0.003). The probability that a given research entity will apply an SPM system, as opposed to other systems, is significantly increased when the health expenditure ratio decreases (a *p*-value of approximately 0.0001), when the perceived health status decreases, when the health care index decreases, and life expectancy at birth increases. Subsequently, a regression analysis was carried out to identify the impact of health expenditure on the selected variables that determine the effectiveness of health care. In the MI system, health expenditure had no significant impact on diabetes mellitus deaths; in the NHS, health expenditure had no significant impact on life expectancy at birth, deaths from acute myocardial infarction and diabetes mellitus deaths; and in the last system (SPM), the impact of health expenditure on the health care index had not been confirmed. When assessing the relations, where an impact has been confirmed, the degree of determination must also be taken into account. When assessing the impact of health expenditure on life expectancy at birth, the NHS funding model appears to be the most effective (*R^2^* = 0.57). NHS, with the MI system, appears to be the most optimal in terms of the perceived health status (MI: *R^2^* = 0.63; NHS: *R^2^* = 0.42). The MI system, together with NHS, seems to be the most effective system, even in terms of the health care index, but it is necessary to point out that it has a low determination coefficient, which is approximately 0.09 for MI and 0.13 for NHS. The largest difference between the systems was seen in diseases that are more typical in developed countries (which are considered OECD countries), meaning the mortality from acute myocardial infarction and diabetes mellitus. Here, the SPM seems to be the most effective. However, it should be pointed out that the coefficient of determination is lower. A correspondence analysis of the health care financing systems and quartile expressions of variables that determine the effectiveness of health care was then conducted. The linkage appears to be significant for all parameters, except death from acute myocardial infarction. When assessing health expenditure and health care financing systems, it can be said that the closest relationship is between the MI system and the highest health expenditure rate. As for life expectancy at birth, the closest relationship to the most positive outcomes is in the NHS system. The NHS also dominates the perceived health status. In the case of the health care index, the most positive values can be linked to the MI and NHS systems. The SPM shows a very close link with the least positive output. As for acute myocardial infarction, the outcomes are confusing, resulting in an insignificant interconnection. Concerning the last relationship, i.e., the interconnection of systems and the number of deaths from diabetes mellitus, it is clear that the most positive outcomes are in the NHS system, and the least positive are in the MI system.

In general, it is believed that it is appropriate to take the funding system into account in health-related analyses; otherwise, the results may be distorted. On the other hand, the findings of previous studies confirmed the significant impact of other socio-economic factors affecting the health of the population, such as social expenditure \[[@B38-ijerph-16-03839]\], income \[[@B1-ijerph-16-03839]\], accessibility to health care \[[@B4-ijerph-16-03839]\], innovation \[[@B59-ijerph-16-03839]\], education \[[@B8-ijerph-16-03839]\], the happiness and well-being of society \[[@B12-ijerph-16-03839]\] and unemployment \[[@B13-ijerph-16-03839]\].

5. Conclusions {#sec5-ijerph-16-03839}
==============

The primary objective of the research in the present study was to determine the effectiveness of health care in classifying health care financing systems from a sample of OECD countries (between 2012 and 2017). As has been pointed out from several points of view, the individual systems do not show the same effectiveness rates. With great caution, it can be accepted that NHS and MI may be considered the most effective systems in general, and SPM seems to be less effective. It is also argued that, regarding effectiveness, there are differences between systems in terms of their predisposition to certain areas of health output. Where one system proves to be ineffective (or its effectiveness is questionable), another system(s) appears to be effective.

The limitations of the presented article lie in its focus on health expenditure and its impact on indicators representing the effectiveness of health care. In the future, the research will focus on verifying and deepening the outlined assumptions, i.e., to determine to what extent funding systems moderate the inputs and outputs of health systems. We plan to expand the portfolio of the analyzed variables to include expenditure items (inputs), health and effectiveness (outputs) and time evaluation (time series).
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###### 

Gross health outputs of the Organization for Economic Cooperation and Development (OECD) countries (based on mean for the period 2012--2017).

  Country           HC_Syste*m*   Expend\_*H*   Life_expec*t*   Self_rep\_*H*   HC_inde*x*   AMId      DIAd
  ----------------- ------------- ------------- --------------- --------------- ------------ --------- ---------
  Australia         NHS           9.03167       82.383          85.200          74.6717      36.620    19.260
  Austria           MI            10.33950      81.417          69.733          80.2350      44.683    28.883
  Belgium           MI            10.32900      81.133          74.417          79.4300      32.480    11.000
  Canada            NHS           10.47967      81.817          88.583          70.6950      37.775    19.050
  Czech Republic    MI            7.35200       78.717          60.650          67.8233      47.400    30.217
  Denmark           NHS           10.18317      80.700          71.667          83.0300      26.725    20.650
  Estonia           SPM           6.21217       77.450          52.383          73.0217      30.640    9.340
  Finland           NHS           9.43467       81.317          68.500          73.4600      51.300    7.400
  France            SPM           11.43650      82.467          67.483          82.0150      18.000    13.150
  Germany           MI            11.02250      80.883          65.100          74.7783      45.680    20.520
  Greece            SPM           8.27700       81.267          74.100          55.1667      44.520    10.140
  Hungary           SPM           7.13433       75.767          57.483          52.4433      54.317    24.367
  Chile             MI            8.01283       79.600          60.533          60.0033      51.440    37.160
  Iceland           NHS           8.21933       82.583          76.380          65.7850      39.567    9.733
  Ireland           NHS           8.75350       81.467          82.617          47.6450      55.600    14.375
  Israel            MI            7.19067       82.217          81.567          80.2233      20.420    39.180
  Italy             NHS           8.93800       82.867          69.267          66.2417      29.425    23.000
  Japan             MI            10.84383      83.750          35.467          84.5583      18.020    6.360
  Korea             SPM           6.96850       81.883          32.567          80.0100      26.360    27.240
  Latvia            NHS           5.69433       74.400          45.883          66.0650      48.025    19.325
  Lithuania         NHS           6.36650       74.617          44.133          68.4767      33.483    9.067
  Luxembourg        SPM           5.62433       82.183          71.500          76.1100      29.340    13.600
  Mexico            MI            5.68717       74.900          65.500          71.4750      134.480   153.200
  Netherlands       MI            10.40267      81.567          76.117          70.5833      29.100    14.980
  New Zealand       NHS           9.36783       81.567          89.183          76.0783      56.000    18.900
  Norway            NHS           9.68067       82.183          77.667          76.5233      46.380    11.540
  Poland            SPM           6.36900       77.533          58.183          58.1983      35.520    19.220
  Portugal          NHS           9.07333       81.067          47.133          66.8917      32.520    31.420
  Slovak Republic   MI            7.10600       76.817          65.917          62.0650      47.367    18.033
  Slovenia          SPM           8.53717       80.850          64.533          65.5067      41.675    13.100
  Spain             NHS           9.01150       83.117          72.917          74.4083      27.080    15.360
  Switzerland       MI            11.71950      83.217          79.767          70.9450      22.660    12.620
  Turkey            SPM           4.31633       77.450          68.183          69.6817      98.380    40.240
  United Kingdom    NHS           9.47117       81.167          71.983          73.5050      35.940    8.280
  United States     MI            16.66000      78.750          87.850          67.5983      36.320    24.460

Note: HC_System: Health Care System; Expend_H: Health expenditure in the percentage of GDP; Life_expect: Life expectancy at birth; Self_rep_H: Perceived health status; HC_index: Health Care Index; AMId: Deaths from acute myocardial infarction; DIAd: Deaths from diabetes mellitus; MI: Multiple insurance funds or companies; NHS: A national health system covering the country as a whole; SPM: A single health insurance fund (single-payer model).

ijerph-16-03839-t002_Table 2

###### 

Descriptive statistics of quantitative variables in the classification of the health care financing systems.

  HC_System   Expend_H   Life_expect   Self_rep_H   HC_index   AMId      DIAd      
  ----------- ---------- ------------- ------------ ---------- --------- --------- -----
  **Total**   ***N***    210           209          208        198       169       169
  *M*         8.72132    80.320        67.399       70.3823    41.904    22.944    
  *σ*         2.325369   2.6279        14.1619      9.55523    22.4545   24.6967   
  **NHS**     ***N***    84            84           83         78        65        65
  *M*         8.83610    80.804        70.727       70.5773    39.165    15.714    
  *σ*         1.372807   2.6960        14.8475      8.78958    9.9542    6.8487    
  **SPM**     ***N***    54            54           54         48        44        44
  *M*         7.20837    79.650        60.713       66.9242    42.918    19.320    
  *σ*         1.963008   2.5097        12.1298      11.45886   23.8262   9.8700    
  **MI**      ***N***    72            71           71         72        60        60
  *M*         9.72214    80.256        68.594       72.4765    44.127    33.435    
  *σ*         2.839983   2.5499        13.2052      8.36971    30.0071   37.8888   
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###### 

Effect size of the health care financing systems (HC_System).

  Dependent Variable   Expend_H   Life_expect   Self_rep_H   HC_index   AMId         DIAd
  -------------------- ---------- ------------- ------------ ---------- ------------ ----------
  Value (*η^2^*)       0.173889   0.030625      0.082944     0.049729   0.009801     0.103041
  Effect size          Medium     Small         Small        Small      Negligible   Small

Note: Negligible: *η^2^* \< 0.02, small: *η^2^ =* 0.02--0.13, *η^2^ =* Mediun 0.13--0.26, Large *η^2^* \> 0.26.
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###### 

Model fit statistic.

  Test output   MCE       Deviance   Hoslem                                                     
  ------------- --------- ---------- --------- ----------- ----------- ---------- --------- --- ----------------
  Model 1 glm   0.25781   0.16129    0.09652   164.73000   113.37000   51.36000   13.4880   8   0.096
  Model 2 glm   0.24219   0.09677    0.14541   170.35000   148.98000   21.37000   34.5900   8   3.175 × 10^5^
  Model 3 glm   0.15625   0.12903    0.02722   146.11400   95.28500    50.82900   87.0820   8   1.776 × 10^15^

Note: Model 1 glm: MI (dependent variable), Expend_H, Life_expect, Self_rep_H, HC_index, AMId, DIAd (independent variables); Model 2 glm: NHS (dependent variable), Expend_H, Life_expect, Self_rep_H, HC_index, AMId, DIAd (independent variables); Model 3 glm: SPM (dependent variable), Expend_H, Life_expect, Self_rep_H, HC_index, AMId, DIAd (independent variables); df: Degrees of freedom; Sig.: asymptotic significance 2 sided.
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###### 

Models' output.

  Test output         Coefficients   Estimate     Std. Error   *z* Value      Sig.
  ------------------- -------------- ------------ ------------ -------------- ----------
  **Model 1 (MI)**    Intercept      18.6161043   12.1882920   1.527          0.126668
  Expend_H            0.8688680      0.2297883    3.781        0.000156       
  Life_expect         −0.3812744     0.1700773    −2.242       0.024976       
  Self_rep_H          0.0005497      0.0182596    0.030        0.975986       
  HC_index            0.0330331      0.0286964    1.151        0.249682       
  AMId                −0.0379316     0.0240201    −1.579       0.114300       
  DIAd                0.1360077      0.0315794    4.307        1.66 × 10^5^   
  **Model 2 (NHS)**   Intercept      −9.635026    8.634763     −1.116         0.26449
  Expend_H            −0.231847      0.140848     −1.646       0.09975        
  Life_expect         0.112180       0.117958     0.951        0.34160        
  Self_rep_H          0.040759       0.018538     2.199        0.02790        
  HC_index            0.011036       0.021793     0.506        0.61259        
  AMId                0.001823       0.015020     0.121        0.90341        
  DIAd                −0.073380      0.025037     −2.931       0.00338        
  **Model 3 (SPM)**   Intercept      −14.70290    10.06726     −1.460         0.14416
  Expend_H            −1.00709       0.26322      −3.826       0.00013        
  Life_expect         0.39186        0.15651      2.504        0.01229        
  Self_rep_H          −0.06377       0.02635      −2.420       0.01552        
  HC_index            −0.07570       0.03161      −2.395       0.01663        
  AMId                0.01956        0.02249      0.870        0.38448        
  DIAd                −0.06013       0.03085      −1.950       0.05123        
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###### 

Regression assumptions, model selection and model representativeness.

  System     Model      *N*                         Model Variable               Unit Roots   Stationary   Outlier   Heteroscedasticityy   Regressioin Model   *R^2^*
  ---------- ---------- --------------------------- ---------------------------- ------------ ------------ --------- --------------------- ------------------- --------
  **MI**     Model 1    71                          Expend_H \--\> Life_expect   0,9749       \<0.01       0.0510    0.2408                OLS                 0.1497
  Model 2    71         Expend_H \--\> Self_rep_H   0.9998                       \<0.01       0.0045       0.3926    LTS                   0.6276              
  Model 3    72         Expend_H \--\> HC_index     0.6009                       \<0.01       0.0043       0.3850    LTS                   0.0946              
  Model 4    60         Expend_H \--\> AMId         0.9981                       \<0.01       0.0006 \*    0.0171    OLS HC3               0.0382              
  Model 5    60         Expend_H \--\> DIAd         0.9848                       \<0.01       0.0016 \*    0.5756    OLS                   0.1429              
  **NHS**    Model 6    84                          Expend_H \--\> Life_expect   0.8630       \<0.01       0.0269    0.0002                OLS HC3             0.5716
  Model 7    83         Expend_H \--\> Self_rep_H   0.9996                       \<0.01       0.0187       0.6007    OLS                   0.4212              
  Model 8    78         Expend_H \--\> HC_index     0.9585                       \<0.01       0.0000       0.1742    LTS                   0.1332              
  Model 9    65         Expend_H \--\> AMId         0.1152                       \<0.01       0.0096       0.0641    LTS                   0.0410              
  Model 10   65         Expend_H \--\> DIAd         0.8851                       \<0.01       0.0034       0.7392    LTS                   0.0389              
  **NHS**    Model 11   54                          Expend_H \--\> Life_expect   0.7907       \<0.01       0.0337    0.0183                OLS HC3             0.2397
  Model 12   54         Expend_H \--\> Self_rep_H   1,0000                       \<0.01       0.0075       0.4002    LTS                   0.2423              
  Model 13   48         Expend_H \--\> HC_index     0.9942                       \<0.01       0.0732       0.3909    OLS                   0.0508              
  Model 14   44         Expend_H \--\> AMId         0.9997                       \<0.01       0.0066       0.0001    OLS HC3               0.2670              
  Model 15   44         Expend_H \--\> DIAd         0.9718                       \<0.01       0.0357       0.0002    OLS HC3               0.2778              

Note: *N*---number of observations entering subsequent analyzes after removal of missing values; Unit Roots---F test for individual effects (*p* Value); Stationary---Augmented Dickey Fuller Test (*p* Value); Outlier---Bonferroni Outlier Test; Heteroscedasticity---Breusch-Pagan Test. \* Mexico 2012--2017 has been removed; OLS: Ordinary Least-Squares Regression; LTS: Least Trimmed Squares Robust Regression; OLS HC3: Heteroskedasticity-Consistent standard error estimators in Ordinary Least-Squares regression.
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###### 

Models' output.

  MI                      NHS     SPM                                                                                                                                         
  ----------------------- ------- ---------------- ---------------- ----------------------- ---------------- -------- ---------------- ------------------------ ----- ------- ----------------
  Model 1 (Life_expect)   *α*     76.90            2.00 × 10^−16^   Model 6 (Life_expect)   *α*              67.68    2.20 × 10^−16^   Model 11 (Life_expect)   *α*   75.14   2.20 × 10^−16^
  *β~1~*                  0.35    8.59 × 10^−4^    *β~1~*           1.48                    3.17 × 10^−13^   *β~1~*   0.63             5.71 × 10^−8^                          
  Model 2 (Self_rep_H)    *α*     48.44            2.00 × 10^−16^   Model 7 (Self_rep_H)    *α*              8.98     2.73 × 10^−1^    Model 12 (Self_rep_H)    *α*   41.02   3.17 × 10^−10^
  *β~1~*                  2.32    2.86 × 10^−14^   *β~1~*           6.98                    3.23 × 10^−11^   *β~1~*   2.67             3.27 × 10^−4^                          
  Model 3 (HC_index)      *α*     64.17            2.00 × 10^−16^   Model 8 (HC_index)      *α*              57.31    2.00 × 10^−16^   Model 13 (HC_index)      *α*   57.43   6.20 × 10^−12^
  *β~1~*                  0.93    9.09 × 10^−3^    *β~1~*           1.66                    1.75 × 10^−3^    *β~1~*   1.29             1.24 × 10^−1^                          
  sModel 4 (AMId)         *α*     45.18            5.84 × 10^−9^    Model 9 (AMId)          *α*              47.97    3.61 × 10^−9^    Model 14 (AMId)          *α*   89.39   5.82 × 10^−9^
  *β~1~*                  −1.91   1.14 × 10^−1^    *β~1~*           −1.25                   1.18 × 10^−1^    *β~1~*   −6.56            3.29 × 10^−4^                          
  Model 5 (DIAd)          *α*     38.38            4.86 × 10^−9^    Model 10 (DIAd)         *α*              7.65     9.36 × 10^−2^    Model 15 (DIAd)          *α*   38.96   2.24 × 10^−7^
  *β~1~*                  −1.56   4.43 × 10^−3^    *β~1~*           0.78                    1.28 × 10^−1^    *β~1~*   −2.77            9.83 × 10^−4^                          
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###### 

Models' prediction with mean health expenditure (8.72).

  MI                      NHS          SPM                                                           
  ----------------------- ------------ ----------------------- ------------ ------------------------ ----------
  Model 1 (Life_expect)   79.91 \*\*   Model 6 (Life_expect)   80.63        Model 11 (Life_expect)   80.60 \*
  Model 2 (Self_rep_H)    68.62        Model 7 (Self_rep_H)    69.87 ^+^    Model 12 (Self_rep_H)    64.30 \*
  Model 3 (HC_index)      72.24 \*\*   Model 8 (HC_index)      71.74 \*\*   Model 13 (HC_index)      \-
  Model 4 (AMId)          \-           Model 9 (AMId)          \-           Model 14 (AMId)          32.16 \*
  Model 5 (DIAd)          24.78 \*\*   Model 10 (DIAd)         \-           Model 15 (DIAd)          14.77 \*

Note: \* *R^2^* \< 0.3; \*\* *R^2^* \< 0.2; ^+^ non-significant constant.
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###### 

Corelation Matrix of analyzed variables total and in the classification of health care financing systems (HC_System).

  Correlation *ρ*   MI        NHS                                                                                     
  ----------------- --------- ----------- ------- -------- -------- -------- ------- ------- ------- ------- -------- --------
  Expend_H                    0.482       0.292   0.173    −0.431   −0.617           0.081   0.460   0.323   0.009    0.085
  Life_expect       0.000                 0.145   0.548    −0.806   −0.513   0.462           0.502   0.013   −0.188   0.022
  Self_rep_H        0.013     0.230               0.050    −0.333   0.015    0.000   0.000           0.213   0.348    0.088
  HC_index          0.147     0.000       0.681            −0.425   −0.246   0.004   0.908   0.063           0.008    0.015
  AMId              0.001     0.000       0.009   0.001             0.586    0.944   0.133   0.005   0.950            −0.263
  DIAd              0.000     0.000       0.910   0.058    0.000             0.499   0.860   0.489   0.911   0.034    
                    **SPM**   **TOTAL**                                                                               
  Expend_H                    0.365       0.072   0.132    −0.248   −0.359           0.490   0.430   0.348   −0.272   −0.225
  Life_expect       0.007                 0.344   0.566    −0.662   −0.286   0.000           0.436   0.381   −0.553   −0.299
  Self_rep_H        0.603     0.011               −0.165   0.201    −0.259   0.000   0.000           0.088   −0.004   −0.042
  HC_index          0.370     0.000       0.261            −0.648   −0.033   0.000   0.000   0.222           −0.382   −0.089
  AMId              0.105     0.000       0.190   0.000             0.361    0.000   0.000   0.963   0.000            0.317
  DIAd              0.017     0.059       0.090   0.841    0.016             0.003   0.000   0.591   0.261   0.000    

Note: A -Expend_H; B - Life_expect; C - Self_rep_H; D - HC_index; E -- AMId; F -- DIAd.
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###### 

Analyzed variables in the country-quartile descriptions (based on mean).

  Country          HC_System   Expend_H   Life_expect   Self_rep_H   HC_index   AMId     DIAd
  ---------------- ----------- ---------- ------------- ------------ ---------- -------- --------
  Australia        NHS         Q2--Q3     Q3            Q3           Q2--Q3     Q1--Q2   Q2--Q3
  Austria          MI          Q3         Q2--Q3        Q2--Q3       Q3         Q2--Q3   Q3
  Belgium          MI          Q2--Q3     Q1--Q2        Q2--Q3       Q3         Q1--Q2   Q1
  Canada           NHS         Q3         Q2--Q3        Q3           Q1--Q2     Q2--Q3   Q2--Q3
  Czech_R          MI          Q1--Q2     Q1            Q1--Q2       Q1--Q2     Q2--Q3   Q3
  Denmark          NHS         Q2--Q3     Q1--Q2        Q2--Q3       Q3         Q1       Q2--Q3
  Estonia          SPM         Q1         Q1            Q1           Q2--Q3     Q1--Q2   Q1
  Finland          NHS         Q2--Q3     Q2--Q3        Q1--Q2       Q2--Q3     Q3       Q1
  France           SPM         Q3         Q3            Q1--Q2       Q3         Q1       Q1--Q2
  Germany          MI          Q3         Q1--Q2        Q1--Q2       Q2--Q3     Q2--Q3   Q2--Q3
  Greece           SPM         Q1--Q2     Q1--Q2        Q2--Q3       Q1         Q2--Q3   Q1
  Hungary          SPM         Q1--Q2     Q1            Q1           Q1         Q3       Q2--Q3
  Chile            MI          Q1--Q2     Q1--Q2        Q1           Q1         Q3       Q3
  Iceland          NHS         Q1--Q2     Q3            Q2--Q3       Q1         Q2--Q3   Q1
  Ireland          NHS         Q1--Q2     Q2--Q3        Q3           Q1         Q3       Q1--Q2
  Israel           MI          Q1--Q2     Q3            Q3           Q3         Q1       Q3
  Italy            NHS         Q1--Q2     Q3            Q1--Q2       Q1--Q2     Q1--Q2   Q2--Q3
  Japan            MI          Q3         Q3            Q1           Q3         Q1       Q1
  Korea            SPM         Q1         Q2--Q3        Q1           Q3         Q1       Q3
  Latvia           NHS         Q1         Q1            Q1           Q1         Q3       Q2--Q3
  Lithuania        NHS         Q1         Q1            Q1           Q1--Q2     Q1--Q2   Q1
  Luxembourg       SPM         Q1         Q2-Q3         Q2--Q3       Q2--Q3     Q1       Q1--Q2
  Mexico           MI          Q1         Q1            Q1--Q2       Q2--Q3     Q3       Q3
  Netherlands      MI          Q3         Q2--Q3        Q2--Q3       Q1--Q2     Q1       Q1-Q2
  New Zealand      NHS         Q2--Q3     Q2--Q3        Q3           Q2--Q3     Q3       Q1-Q2
  Norway           NHS         Q2--Q3     Q2--Q3        Q3           Q3         Q2-Q3    Q1
  Poland           SPM         Q1         Q1            Q1           Q1         Q1-Q2    Q2-Q3
  Portugal         NHS         Q2--Q3     Q1--Q2        Q1           Q1--Q2     Q1-Q2    Q3
  Slovak_R         MI          Q1         Q1            Q1--Q2       Q1         Q2-Q3    Q1-Q2
  Slovenia         SPM         Q1--Q2     Q1--Q2        Q1--Q2       Q1         Q2--Q3   Q1--Q2
  Spain            NHS         Q2--Q3     Q3            Q2--Q3       Q2--Q3     Q1       Q1--Q2
  Switzerland      MI          Q3         Q3            Q3           Q1--Q2     Q1       Q1--Q2
  Turkey           SPM         Q1         Q1            Q1--Q2       Q1--Q2     Q3       Q3
  United Kingdom   NHS         Q2--Q3     Q1--Q2        Q2--Q3       Q2--Q3     Q1--Q2   Q1
  United States    MI          Q3         Q1--Q2        Q3           Q1--Q2     Q1--Q2   Q2--Q3
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###### 

Correspondence Analysis -- quantitative relevancy.

  Test output                             Expend_H        Life_expect     Self_rep_H      HC_index        AMId            DIAd
  -------------------- ------------------ --------------- --------------- --------------- --------------- --------------- ---------
  Eigenvalues          Variance (Dim 1)   0.3720          0.0740          0.1700          0.1150          0.0690          0.1370
  \% of var. (Dim 1)   65.7930            81.8040         78.6160         71.2470         99.3840         97.5630         
  Variance (Dim 2)     0.1930             0.0160          0.0460          0.0470          0.0000          0.0030          
  \% of var. (Dim 2)   34.2070            18.1960         21.3840         28.7530         0.6160          2.4370          
  *Χ^2^*               Value              118.7589        18.9051         45.0550         32.0890         11.7886         23.7699
  Sig.                 2.97 × 10^−23^     4.33 × 10^−3^   4.56 × 10^−8^   1.57 × 10^−5^   6.69 × 10^-2^   5.76 × 10^−4^   
  Correlation (*π*)    0.7520             0.3008          0.4654          0.4026          0.2641          0.3750          
